期刊文献+

生物药物研发进展及应用

Application and Development of Biopharmceutics
下载PDF
导出
摘要 随着传统新药研制成本和难度的加大,人类DNA重组技术、基因工程、蛋白质工程及“组”学的发展,生物制药正成为制药领域的新星,为广大患者带来了福音。本文就国内外生物药物的研发进展及应用情况做了概述。 With the development ot the tecnmques of recombinant DNA technology,genetic engineering, protein engineering and with the increasing cost and difficulty of developing new traditional drugs, pharmaceutical drugs that take advantage of those technologies become rising stars in this area. These years, bio-drugs have already brought good performance into the pharmaceutical industry. In this review, we summarized the current situation and the rising field in biopharmaceutical industry home and abroad.
作者 彭洪薇 王锐
出处 《药品评价》 CAS 2011年第22期4-6,10,共4页 Drug Evaluation
关键词 生物药物 重组蛋白质药物 生物技术疫苗 基因药物 Biopharmaceutics Recombinant protein drugs Biotech vaccine Gene drugs
  • 相关文献

参考文献21

  • 1Gary Walsh. Biopharmaceuticals: Biochemistry and biotechnology[M]. Second Edition(2003). John Wiley & Sons Ltd, ISBN0-470-84326-8.
  • 2Walsh, G. Biopharmaceutic benchmarks-2003[J]. Nat. Biotechnol. 2003; 2l(2):870-878.
  • 3Bibby, K., Davis, J., Jones, C.Biopharmaceuticals - Moving to Centre Stage[M].BioPeople North, American Biotechnology Industry and Suppliers' Guide.2003:3-11.
  • 4Beijing Pharma and Biotech Center, Annual report for development of Beijing Pharma & Biotech industry: 2005[R]. China Science Press,2005:78-106.
  • 5胡显文,陈惠鹏,张树庸.全球生物制药产业概况[J].中国医药生物技术,2009,4(2):85-89. 被引量:22
  • 6Hu, X. W., Ma, Q. J., Zhang, S. Y. Biopharmaceuticals in China[J]. Biotechnol,2006,1:12 I5 - 1224.
  • 7朱迅.医药生物技术及生物技术药物(一)[J].中国医药技术经济与管理,2009,3(10):45-52. 被引量:4
  • 8李守新,刘文励.血液病的细胞因子治疗[J].内科急危重症杂志,1996,2(3):133-135. 被引量:2
  • 9Schofleld J. R., Robinson W.A., Murphy J. R., et al. Low doses of Interferon-or are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia[J]. Ann Inter Med, 1994,121(10):736-743.
  • 10Bailon,P., Won CY. PEG-modified biopharmaceuticals[J]. Expert Opin .DrugDeliv.2009;6( 1 ): 1 - 16.

二级参考文献34

  • 1胡显文,陈惠鹏,汤仲明,马清钧.生物制药的现状和未来(一):历史与现实市场[J].中国生物工程杂志,2004,24(12):95-101. 被引量:37
  • 2胡显文,陈惠鹏,汤仲明,马清钧.生物制药的现状和未来(二):发展趋势与希望[J].中国生物工程杂志,2005,25(1):86-93. 被引量:32
  • 3胡显文,陈惠鹏,汤仲明,马清钧.美国、欧盟和中国生物技术药物的比较[J].中国生物工程杂志,2005,25(2):82-94. 被引量:33
  • 4章金刚,倪道明.生物制品的现状与展望[J].中国输血杂志,2006,19(5):349-351. 被引量:8
  • 5Jaffe E S, Harris N L, Stein H, et al. Pathology & genetics tumours of haematopietic and lymphoid tissues. World Health Organization classification of turnouts [M ]. Lyon: IARC Press, 2001 : 239-253.
  • 6Marafioti T, Hummel M, Foss H D, et al. Hodgkin and Reed- Sternberg cells represent an expansion of a single clone originating from a germinal center B cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription [J]. Blood, 2000,95 (4) : 1443- 1450.
  • 7Schmid C, Pan L, Diss T, et al. Expression of B cell antigens by Hodgkin's and Reed-Sternberg cells [J]. Am J Pathol, 1991,139(4) :701-707.
  • 8Tzankon A, Zimpfer A, Pehrs AC, et al. Expression of B-cell markers in classical Hodgkin lymphoma: a tissue microarray analysis of 330 cases [J]. Mod Pathol, 2003,16(11 ): 1141- 1147.
  • 9von Wasielewski R, Mengel M, Fisher R, et al. Classical Hodgkin's disease: clinical impact of the immunophenotype [J]. Am J Pathol, 1997,151(4):1123-1130.
  • 10Rassidakis G Z, Medeiros L J, Viviani S, et al. CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hndgkin's disease: associations with presenting features and clinical outcome [J]. J Clin Oncol, 2002,:20(5):1278-1287.

共引文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部